1H26 Appendix 4D and Financial Report
Filed with ASX · · 26 pages · English
Underlying net profit amounted to $10,410,000, at the upper end of the November 2025 updated guidance. (1) The Directors consider EBITDA to be one of the key financial measures of the underlying performance of Monash IVF Group Limited. EBITDA is earnings before interest, tax, depreciation and amortisation. EBITDA is a non-IFRS measure which is used by the Group as a key indicator of underlying per
In the deck
Story so far
Earlier from Monash IVF
- NBIO withdrawn to acquire Monash IVF
- Monash IVF rejects NBIO proposal to acquire MVF
- 2025 AGM - Investor Presentation
- 2025 AGM - Chair Address
- Appointment of Chief Executive Officer and Managing Director
Later from Monash IVF
- MVF delivers 1H26 Underlying NPAT of $10.4m
- 1H26 Results Presentation
- Revised NBIO to acquire MVF
- Monash IVF rejects revised non-binding indicative proposal
- Trading update
Follow Monash IVF into a list and get an email when it puts out news.
Follow Monash IVF